RESUMEN
In vivo imaging system(IVIS)is a new and rapidly expanding technology,which has a wide range of applications in life science such as cell tracing.By counting the number of photons emitted from a specimen,IVIS can quantify biological events such as tumor growth.We used B16F10-luc-G5 tumor cells and 20 Babl/C mice injected subcutaneously with B16F10-luc-G5 tumor cells(1×106 in 100 μL)to develop a method to quantitatively analyze cells traced by IVIS in vitro and in vivo,respectively.The results showed a strong correlation between the number of tumor cells and the intensity of bioluminescence signal(R2=0.99)under different exposure conditions in in vitro assay.The results derived from the in vivo experiments showed that tumor luminescence was observed in all mice by IVIS at all days,and there was significant difference(P<0.01)between every two days from day 3 to day 14.Moreover,tumor dynamic morphology could be monitored by IVIS when it was invisible.There was a strong correlation between tumor volume and bioluminescence signal(R2=0.97)by IVIS.In summary,we demonstrated a way to accurately carry out the quantitative analysis of cells using IVIS both in vitro and in vivo.The data indicate that IVIS can be used as an effective and quantitative method for cell tracing both in vitro and in vivo.
RESUMEN
To identify acute renal allograft rejection biomarkers in human serum, two-dimensional differential in-gel electrophoresis (2-D DIGE) and reversed phase high-performance liquid chromatog-raphy (RP-HPLC) followed by electrospray ionization mass spectrometry (ESI-MS) were used. Serum samples from renal allograft patients and normal volunteers were divided into three groups: acute rejec-tion (AR), stable renal function (SRF) and normal volunteer (N). Serum samples were firstly processed using Multiple Affinity Removal Column to selectively remove the highest abundance proteins. Differ-entially expressed proteins were analyzed using 2-D DIGE. These differential protein spots were ex-cised, digested by trypsin, and identified by RP-HPLC-ESI/MS. Twenty-two differentially expressed proteins were identified in serum from AR group. These proteins included complement C9 precursor,apolipoprotein A-Ⅳ precursor, vitamin D-binding protein precursor, beta-2-glycoprotein 1 precursor,etc. Vitamin D-binding protein, one of these proteins, was confirmed by ELISA in the independent set of serum samples. In conclusion, the differentially expressed proteins as serum biomarker candidates may provide the basis of acute rejection noninvasive diagnosis. Confirmed vitamin D-binding protein may be one of serum biomarkers of acute rejection. Furthermore, it may provide great insights into un-derstanding the mechanisms and potential treatment strategy of acute rejection.